Slack pursued an unusual direct listing, meaning it did not have banks underwrite the offering.CNBC Disruptor 50read more
Slack's CEO said that the company didn't want to go public via an IPO so that it could be as transparent and accessible as possible.Deals and IPOsread more
Oil jumped as much as 6% on Thursday after Iran shot down a U.S. military drone, prompting President Trump to blast Tehran on Twitter.Energy Commoditiesread more
President Donald Trump on Thursday told reporters that he thinks the Iranian strike on an American drone was unintentional.Politicsread more
For doubters thinking the rally is just a last gasp of the decade-long bull market, chart analysts are here to prove them wrong.Marketsread more
Notorious "pharma bro" Martin Shkreli has reached a settlement with his former biopharmaceutical company Retrophin just weeks ago after he sued two company directors and its...Biotech and Pharmaceuticalsread more
"The slowdown in the global economy is reaching this shore," veteran trader Art Cashin says.Economyread more
Slack's public market debut on Thursday will generate billions for venture firm Accel and healthy returns for Andreessen Horowitz and Social CapitalTechnologyread more
JetBlue is ordering the longest-range Airbus jets to expand service to more European cities.Airlinesread more
Apple announced on Thursday that it will recall some 15-inch MacBook Pro laptops because they have batteries that may "overheat and pose a fire safety risk."Technologyread more
Health-care stocks have caught a cold this year, but one technical analyst sees the beginnings of a recovery.Trading Nationread more
(Repeats story transmitted earlier with no changes to text)
Feb 25 (Reuters) - Bayer AG is set to face a second U.S. jury over allegations that its popular glyphosate-based weed killer Roundup causes cancer, six months after the company's share price was rocked by a $289 million verdict in California state court.
A lawsuit by California resident Edwin Hardeman against the company was scheduled to begin on Monday in federal rather than state court. The trial is also a test case for a larger litigation. More than 760 of the 9,300 Roundup cases nationwide are consolidated in the federal court in San Francisco that is hearing Hardeman's case.
Bayer denies all allegations that Roundup or glyphosate cause cancer, saying decades of independent studies have shown the world's most widely used weed killer to be safe for human use and noting that regulators around the world have approved the product.
Under a January ruling by U.S. District Judge Vince Chhabria, who presides over the federal litigation, jurors in Hardeman's case will not initially hear all the evidence presented in last year's California trial.
Chhabria called evidence by plaintiffs that the company allegedly attempted to influence regulators and manipulate public opinion "a distraction" from the science in the cases. He said such evidence should only go before the jury in a second trial phase that would only take place if they determined Roundup caused Hardeman's cancer.
Evidence of corporate misconduct was seen as playing a key role in the finding by a California state court jury in August that Roundup caused another man's non-Hodgkin's lymphoma and that Bayer's Monsanto unit failed to warn consumers about the weed killer's cancer risks. That jury's $289 million damages award was later reduced to $78 million.
Bayer's share price dropped 10 percent following the verdict and has remained volatile.
Hardeman began using the Roundup brand herbicide with glyphosate in the 1980s to control poison oak and weeds on his property and sprayed "large volumes" of the chemical for many years on a regular basis, according to court documents. He was diagnosed with non-Hodgkin's lymphoma, a cancer of the lymph system, in February 2015 and filed his lawsuit a year later.
But Hardeman has a history of hepatitis C, a risk factor for developing lymphoma. Bayer in court filings also said the majority of non-Hodgkin's lymphoma incidents are idiopathic, or have no known cause.
Plaintiffs criticized Chhabria's order dividing the trial and restricting evidence as "unfair," saying their scientific evidence allegedly showing glyphosate causes cancer is inextricably linked to Monsanto's alleged wrongful conduct. (Reporting by Tina Bellon in New York; Editing by Cynthia Osterman and Jonathan Oatis)